SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis

Inflammation is undoubtedly a hallmark of cancer development. Its maintenance within tumors and the consequences on disease aggressiveness are insufficiently understood.

Source: Molecular Cancer - March 17, 2023 Category: Cancer & Oncology Authors: Abdel Jelil Njouendou, Tibor Szarvas, Arnol Auvaker Zebaze Tiofack, Rovaldo Nguims Kenfack, Pamela Derliche Tonouo, Sidonie Noa Ananga, Esther H. M. Dina Bell, Gustave Simo, J örg D. Hoheisel, Jens T. Siveke and Smiths S. Lueong Tags: Correspondence Source Type: research